Biofrontera Inc. (Biofrontera) is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions. With a focus on the fields of photodynamic therapy (PDT) and topical antibiotics, Biofrontera currently commercializes the FDA-approved flagship drug Ameluz® (aminolevulinic acid hydrochloride gel, 10%) in the United States. When used in combination with PDT and Biofrontera’s BF-RhodoLED® lamp, Ameluz®-PDT is indicated for the treatment of actinic keratoses (AK), one of the most common precancerous skin conditions. Biofrontera also commercializes the drug Xepi® (ozenoxacin cream, 1%), FDA-approved for the treatment of impetigo. In collaboration with dermatologists, Biofrontera is fully committed to advancing treatment options and patient care.
120 Presidential Way, Suite 330
Woburn, MA 01801
1-781-245-1325
info-us@biofrontera.com
Investor Relations
ir@bfinc.com
120 Presidential Way, Suite 330
Woburn, MA 01801
1-781-245-1325
info-us@biofrontera.com
INVESTOR RELATIONS CONTACT
Pamela Keck
+49-214-87632-92
us-ir@biofrontera.com
© Copyright 2021, Biofrontera Corp. All rights reserved.